The Phase I study is testing a bispecific antibody, XmAb14045, in acute myeloid leukemia, under a partnership with Swiss drugmaker Novartis. Xencor's stock fell following the news.
The drugmaker said Monday that it had signed a deal with Teneobio to develop a BCMA-targeting bispecific antibody.
As technology advances, AI-powered tools will increasingly reduce the administrative burdens on healthcare providers.
CAR-Ts have generated excitement, but bispecific monoclonal antibodies may continue to have a competitive edge in some cases.